|
GB8808015D0
(en)
|
1988-04-06 |
1988-05-05 |
Ritter M A |
Chemical compounds
|
|
AU643427B2
(en)
|
1988-10-31 |
1993-11-18 |
Immunex Corporation |
Interleukin-4 receptors
|
|
EP0668774A1
(en)
|
1991-05-03 |
1995-08-30 |
Seragen, Inc. |
Interleukin receptor targeted molecules for treatment of inflammatory arthritis
|
|
JP3315427B2
(ja)
|
1992-03-05 |
2002-08-19 |
大日本除蟲菊株式会社 |
皮膚炎治療剤
|
|
US5714146A
(en)
|
1992-08-26 |
1998-02-03 |
Board Of Regents Of The University Of Washington |
IL-4 bone therapy
|
|
EP0604693A1
(en)
|
1992-12-29 |
1994-07-06 |
Schering-Plough |
Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
|
|
ZA946875B
(en)
|
1993-09-07 |
1995-07-06 |
Smithkline Beecham Corp |
Recombinant il4 antibodies useful in treatment of il4 mediated disorders
|
|
ES2259478T3
(es)
|
1998-09-18 |
2006-10-01 |
Dynavax Technologies Corporation |
Metodos para tratar trastornos asociados con la ige y composiciones para este uso.
|
|
US6927044B2
(en)
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
|
WO2001092340A2
(en)
|
2000-05-26 |
2001-12-06 |
Immunex Corporation |
Use of interleukin-4 antagonists and compositions thereof
|
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
EP1304115B1
(en)
|
2000-07-26 |
2007-09-12 |
Hououdou Co. Ltd. |
Antipruritic compositions and compositions promoting wound healing
|
|
PT1345624E
(pt)
|
2000-12-22 |
2006-09-29 |
Nestle Sa |
Inducao de tolerancia
|
|
US20030103938A1
(en)
|
2001-05-09 |
2003-06-05 |
Alk-Abello A/S |
Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
|
|
US20050031609A1
(en)
|
2001-05-11 |
2005-02-10 |
Thomas Hultsch |
Compositions for use in treating ige-associated disorders
|
|
US20050074462A1
(en)
|
2001-05-23 |
2005-04-07 |
Duotol Ab |
Supression of allergic reactions by transdermal administration of allergens conjugated to cholera toxin or fragments thereof
|
|
AR037456A1
(es)
|
2001-11-30 |
2004-11-10 |
Biogen Inc |
Anticuerpos contra proteinas quimiotacticas monocitarias
|
|
CA2479927C
(en)
|
2002-03-29 |
2013-03-12 |
Schering Corporation |
Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
|
|
MXPA05005528A
(es)
|
2002-11-26 |
2006-04-05 |
Alk Abello As |
Producto farmaceutico de alergeno.
|
|
PT2000481E
(pt)
|
2003-02-01 |
2016-06-17 |
Tanox Inc |
Anticorpos anti-ige humana de alta afinidade
|
|
US7923209B2
(en)
|
2003-03-14 |
2011-04-12 |
Anergis, S.A. |
Allergen peptide fragments and use thereof
|
|
CA2543982C
(en)
|
2003-11-07 |
2013-01-08 |
Immunex Corporation |
Antibodies that bind interleukin-4 receptor
|
|
AU2004309373A1
(en)
|
2003-12-22 |
2005-07-14 |
Amgen Inc. |
Methods for identifying functional antibodies
|
|
DE602005006758D1
(de)
|
2004-02-27 |
2008-06-26 |
Regeneron Pharma |
Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
|
|
US20090098142A1
(en)
|
2004-06-09 |
2009-04-16 |
Kasaian Marion T |
Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
|
|
AR049390A1
(es)
*
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
|
JP5234445B2
(ja)
|
2004-10-05 |
2013-07-10 |
源一郎 杣 |
薬剤
|
|
US8030003B2
(en)
|
2004-12-07 |
2011-10-04 |
Children's Hospital Medical Center |
Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
|
|
TWI306862B
(en)
|
2005-01-03 |
2009-03-01 |
Hoffmann La Roche |
Antibodies against il-13 receptor alpha 1 and uses thereof
|
|
AU2006244180B2
(en)
|
2005-05-06 |
2012-03-01 |
Zymogenetics, Inc. |
IL-31 monoclonal antibodies and methods of use
|
|
US8679545B2
(en)
|
2005-11-12 |
2014-03-25 |
The Regents Of The University Of California |
Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
|
|
US8324192B2
(en)
|
2005-11-12 |
2012-12-04 |
The Regents Of The University Of California |
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
|
|
JP5307708B2
(ja)
|
2006-06-02 |
2013-10-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒトｉｌ−６受容体に対する高親和性抗体
|
|
JP4221018B2
(ja)
|
2006-08-31 |
2009-02-12 |
トヨタ自動車株式会社 |
頭部保護エアバッグ装置
|
|
CA2664343C
(en)
|
2006-10-02 |
2016-04-26 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human il-4 receptor
|
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
UA102994C2
(ru)
|
2007-03-22 |
2013-09-10 |
Дженентек, Инк. |
АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧНО СВЯЗЫВАЕТСЯ С IgE/M1' И ИНДУЦИРУЕТ АПОПТОЗ В ЭКСПРЕССИРУЮЩИХ IgE В-КЛЕТКАХ
|
|
EP2022507A1
(en)
|
2007-08-07 |
2009-02-11 |
Universität Hamburg |
Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
|
|
WO2009061819A1
(en)
|
2007-11-05 |
2009-05-14 |
The Regents Of The University Of Colorado |
Minimally-invasive measurement of esophageal inflammation
|
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
|
DE202008006598U1
(de)
|
2008-04-11 |
2008-10-02 |
Alk-Abelló A/S |
Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
|
|
US20090264392A1
(en)
|
2008-04-21 |
2009-10-22 |
Meritage Pharma, Inc. |
Treating eosinophilic esophagitis
|
|
WO2010065557A2
(en)
|
2008-12-01 |
2010-06-10 |
Cincinnati Children's Hospital Medical Center |
Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
|
|
WO2010120511A2
(en)
|
2009-03-31 |
2010-10-21 |
Altair Therapeutics, Inc. |
Method of treating respiratory disorders
|
|
US8497528B2
(en)
|
2010-05-06 |
2013-07-30 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Method for fabricating a strained structure
|
|
CA2773234C
(en)
|
2009-09-07 |
2017-11-28 |
Dbv Technologies |
Method of treating eosinophilic esophagitis
|
|
US8993347B2
(en)
|
2009-12-17 |
2015-03-31 |
Cornell University |
Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
|
|
EP3970726A1
(en)
|
2010-06-24 |
2022-03-23 |
ViroPharma Biologics LLC |
Methods of treatment for esophageal inflammation
|
|
SG189220A1
(en)
|
2010-10-06 |
2013-05-31 |
Regeneron Pharma |
Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
|
|
HRP20180421T1
(hr)
|
2010-11-17 |
2018-04-20 |
Chugai Seiyaku Kabushiki Kaisha |
Višestruko specifične molekule za vezanje na antigen koje imaju alternativnu funkciju u odnosu na funkciju faktora viii zgrušavanja krvi
|
|
RU2453303C1
(ru)
|
2010-12-23 |
2012-06-20 |
Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") |
Фармацевтическая композиция для лечения атопического дерматита
|
|
WO2012094643A2
(en)
|
2011-01-06 |
2012-07-12 |
Children's Hospital Medical Center |
Esophageal cytokine expression profiles in eosinophilic esophagitis
|
|
US20130052190A1
(en)
|
2011-02-22 |
2013-02-28 |
Oxagen Limited |
CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
|
|
AU2012272858B2
(en)
|
2011-06-21 |
2017-03-09 |
Children's Hospital Medical Center |
Diagnostic methods for eosinophilic esophagitis
|
|
US8790651B2
(en)
|
2011-07-21 |
2014-07-29 |
Zoetis Llc |
Interleukin-31 monoclonal antibody
|
|
CN103974706A
(zh)
|
2011-10-06 |
2014-08-06 |
N·V·努特里奇亚 |
嗜酸细胞性食管炎的治疗
|
|
CA2859284A1
(en)
|
2011-12-16 |
2013-06-20 |
Atopix Therapeutics Limited |
Combination of a crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
|
|
JP2015506950A
(ja)
|
2012-01-31 |
2015-03-05 |
ジェネンテック， インコーポレイテッド |
抗ｉｇ−ｅｍ１’抗体およびそれを用いる方法
|
|
WO2013155010A1
(en)
|
2012-04-09 |
2013-10-17 |
Children's Hospital Medical Center |
Non-invasive biomarkers for eosinophilic esophagitis
|
|
TWI656880B
(zh)
*
|
2012-08-21 |
2019-04-21 |
法商賽諾菲生物技術公司 |
投與ｉｌ－４ｒ拮抗劑以治療或預防氣喘之方法
|
|
HUE039387T2
(hu)
*
|
2012-09-07 |
2018-12-28 |
Regeneron Pharma |
Atópiás dermatitisz kezelési módszerei egy IL-4R antagonista adagolásával
|
|
US10132809B2
(en)
|
2012-10-10 |
2018-11-20 |
Rhote Island Hospital |
Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
|
|
JP2016507523A
(ja)
|
2013-02-05 |
2016-03-10 |
エンクマフ アーゲー |
ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
|
|
TWI755763B
(zh)
|
2013-06-04 |
2022-02-21 |
美商再生元醫藥公司 |
藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
|
|
SI3010539T1
(sl)
|
2013-06-21 |
2019-11-29 |
Regeneron Pharma |
Postopki za zdravljenje nazalne polipoze z administriranjem antagonista IL-4R
|
|
TWI634900B
(zh)
|
2013-07-11 |
2018-09-11 |
再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
|
|
RU2552929C1
(ru)
|
2013-11-14 |
2015-06-10 |
Общество С Ограниченной Ответственностью "Фарминтерпрайсез" |
Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
|
|
IL315136A
(en)
|
2014-02-21 |
2024-10-01 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4rantagonist
|
|
AU2015222951B2
(en)
|
2014-02-28 |
2020-06-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating skin infection by administering an IL-4R antagonist
|
|
WO2016077675A1
(en)
|
2014-11-14 |
2016-05-19 |
Sanofi Biotechnology |
Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
|
|
WO2017143270A1
(en)
|
2016-02-19 |
2017-08-24 |
Regeneron Pharmaceuticals, Inc. |
Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
|
|
TWI728172B
(zh)
|
2016-08-18 |
2021-05-21 |
美商愛戴爾製藥股份有限公司 |
治療嗜伊紅性食道炎之方法
|
|
CN109789196B
(zh)
|
2016-09-01 |
2024-03-19 |
瑞泽恩制药公司 |
用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
|
|
KR20230006049A
(ko)
|
2016-09-22 |
2023-01-10 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
|
|
KR20190116420A
(ko)
|
2017-02-17 |
2019-10-14 |
프레드 헛친슨 켄서 리서치 센터 |
Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법
|
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2019028367A1
(en)
|
2017-08-04 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
|
|
PT3515465T
(pt)
|
2017-08-18 |
2024-03-04 |
Regeneron Pharma |
Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
|
|
ES2969049T3
(es)
|
2017-10-30 |
2024-05-16 |
Sanofi Biotechnology |
Antagonista de IL-4R para uso en un método para tratar o prevenir el asma
|
|
SG11202009371WA
(en)
|
2018-05-13 |
2020-10-29 |
Regeneron Pharma |
Methods for treating atopic dermatitis by administering an il-4r inhibitor
|
|
CA3103151A1
(en)
|
2018-06-14 |
2019-12-19 |
Ajinomoto Co., Inc. |
Compound having affinity substance to antibody and bioorthogonal functional group, or salt thereof
|
|
CN121102493A
(zh)
|
2019-03-21 |
2025-12-12 |
瑞泽恩制药公司 |
用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
|
|
MX2021013427A
(es)
|
2019-05-01 |
2022-01-31 |
Sanofi Biotechnology |
Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
|
|
SG11202113312VA
(en)
|
2019-08-05 |
2021-12-30 |
Regeneron Pharma |
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
|
|
EP4010373A1
(en)
|
2019-08-05 |
2022-06-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
MX2022006992A
(es)
|
2019-12-09 |
2022-07-13 |
Sanofi Biotechnology |
Metodos para tratar los trastornos relacionados con il-4/il-13 identificados digitalmente.
|
|
KR20220158821A
(ko)
|
2020-03-27 |
2022-12-01 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
|
|
JP2023527775A
(ja)
|
2020-05-22 |
2023-06-30 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法
|
|
CA3194111A1
(en)
|
2020-10-05 |
2022-04-14 |
Christine XU |
Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
|
|
MX2023007945A
(es)
|
2021-01-08 |
2023-09-21 |
Regeneron Pharma |
Metodos para tratar la alergia al cacahuate y mejorar la inmunoterapia especifica de alergeno del cacahuate mediante la administracion de un antagonista de il-4r.
|